Search company, investor...
Verge Genomics company logo

Verge Genomics

Founded Year



Series B | Alive

Total Raised


Last Raised

$98M | 1 yr ago

Mosaic Score
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

+40 points in the past 30 days

About Verge Genomics

Verge Genomics works to discover drugs for neurodegenerative diseases using computational genomics.

Headquarters Location

2 Tower Place

South San Francisco, California, 94080,

United States

Missing: Verge Genomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Verge Genomics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Life Sciences / Biopharma Tech

The companies in this market are analyzing data (e.g., clinical trial data, EHRs, omics data, cellular images, and more) to discover novel drug candidates. Machine learning alone is no longer a differentiator. Startups are increasingly beginning to incorporate laboratory automation and experimentation to create high-quality biological data to train their algorithms.

Verge Genomics named as Highflier among 14 other companies, including Atomwise, Terray Therapeutics, and Healx.

Missing: Verge Genomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Verge Genomics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Verge Genomics in 2 CB Insights research briefs, most recently on Feb 22, 2022.

Expert Collections containing Verge Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verge Genomics is included in 4 Expert Collections, including Biopharma Tech.


Biopharma Tech

6,079 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Drug Discovery Tech Market Map

221 items

This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.

Latest Verge Genomics News

Verge Genomics to Present at Upcoming Investor Conferences in November

Nov 21, 2022

Piper Sandler 34th Annual Healthcare Conference on November 29 Evercore ISI HealthCONx Conference 2022 on November 30 November 21, 2022 08:00 AM Eastern Standard Time SAN FRANCISCO--( BUSINESS WIRE )--Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Alice Zhang, CEO and co-founder of Verge Genomics, will present at both the Piper Sandler 34th Annual Healthcare Conference on November 29 in New York, and the 5th Annual Evercore ISI HealthCONx Conference 2022 on November 30. Please see additional information below: Piper Sandler 34th Annual Healthcare Conference Presentation: Tuesday, November 29 5th Annual Evercore ISI HealthCONx Conference 2022 Presentation: Wednesday, November 30 About Verge Genomics Verge uses AI and human data to develop better drugs faster for the most challenging diseases of our generation. Verge has built CONVERGE™, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development. Its pioneering use of the industry’s most advanced all-in-human, AI-powered drug discovery platform identifies new medicines more efficiently and with an improved probability of success. Verge is one of the first AI-enabled drug discovery companies to independently develop a clinical candidate from a novel target discovered from its platform. Verge has further demonstrated the power of CONVERGE™ by delivering a broad pipeline spanning diverse therapeutic areas, with its first program, an investigational PIKfyve inhibitor for the treatment of ALS, now in the clinic. The company is led by experienced drug developers and computational biologists with a shared belief that technology has created a new opportunity to deliver life-changing medicines more efficiently. For additional information, please visit . Follow us on LinkedIn and Twitter . Contacts

Verge Genomics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verge Genomics Rank

Verge Genomics Frequently Asked Questions (FAQ)

  • When was Verge Genomics founded?

    Verge Genomics was founded in 2015.

  • Where is Verge Genomics's headquarters?

    Verge Genomics's headquarters is located at 2 Tower Place, South San Francisco.

  • What is Verge Genomics's latest funding round?

    Verge Genomics's latest funding round is Series B.

  • How much did Verge Genomics raise?

    Verge Genomics raised a total of $134.12M.

  • Who are the investors of Verge Genomics?

    Investors of Verge Genomics include ALS Investment Fund, Threshold Ventures, Section 32, Tao Capital Partners, Lifeforce Capital and 17 more.

  • Who are Verge Genomics's competitors?

    Competitors of Verge Genomics include Terray Therapeutics and 2 more.

Compare Verge Genomics to Competitors

Insilico Medicine Logo
Insilico Medicine

Insilico Medicine develops a range of Generative Adversarial Networks (GANs) and reinforcement learning approaches to identify protein targets, generate molecular structures with specified properties, and generate synthetic data. The company provides pharmaceutical and biotechnology companies with artificial intelligence solutions for research and development. It was founded in 2014 and is based in Hong Kong.

Atomwise Logo

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

NuMedii Logo

NuMedii discovers and de-risks effective new drugs by translating its predictive Big Data technology into therapies with a higher probability of therapeutic success. The company's Big Data technology consists of billions of data points of ever-increasing amounts of comprehensive disease, pharmacological and clinical data. NuMedii integrates these data with network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. The company has successfully validated its Big Data technology as six of six drug candidates have demonstrated preclinical activity for the predicted new indication. NuMedii will partner with pharmaceutical companies for the development and commercialization of its therapeutic candidates.

BioLizard Logo

BioLizard is a bioinformatics and AI company that provides multi-omics data analysis, algorithm development, data mining and integration, and pipeline and app development for scientific data needs. It is based in Ghent, Belgium.

Delta 4

Delta 4 is a drug discovery and development company combining in-silico drug discovery and big data analysis with expertise in molecular biology and clinical development to a powerful proprietary drug discovery platform. This platform generates promising drug candidates annotated with biological and medical information, resulting in a fast-track to establish a clinical proof of concept. The Company focuses on the discovery of indications for approved drugs (drug repositioning). In its first therapeutic area, focal segmental glomerulosclerosis (FSGS), a devastating renal disease with high and urgent medical need, Delta 4 has identified and pre-clinically validated promising drug candidates that are currently prepared for clinical proof-of-concept. In 2020, the Company applied its drug discovery platform to additional indications. As a result, Delta 4 has readied a potential COVID-19 therapy for Phase 1 development and filed four patent applications for compounds in two indications.

Aria Pharmaceuticals Logo
Aria Pharmaceuticals

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company that discovers and develops novel small molecule therapies for complex and hard-to-treat diseases

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.